TPD52 and neoplasm: In summary, aberrant accumulation of the PrLZ oncoprotein due to clinical SPOP mutation or abnormal activation of ERK1/2 in PCa could be the underlying molecular mechanisms driving tumor progression and resulting in poor survival of PCa patients (Fig. 7).